ストックスクリーナーアプリを入手
13.35
1.11%
-0.15
アフターアワーズ：
13.35
前日終値:
$13.50
開ける：
$13.52
24時間の取引高:
382.31K
Relative Volume:
0.37
時価総額：
$903.08M
収益：
-
当期純損益:
$-119.67M
株価収益率:
-4.8901
EPS:
-2.73
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
+9.52%
1か月 パフォーマンス:
-6.12%
6か月 パフォーマンス:
-3.82%
1年 パフォーマンス:
+11.25%
1日の値動き範囲:
$12.90
$13.87
1週間の範囲:
$11.77
$14.83
52週間の値動き範囲:
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
13.35 | 903.08M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 By Investing.com - Investing.com Canada
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock - Investing.com Australia
Mineralys Therapeutics chief medical officer sells $165,185 in stock - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com - Investing.com India
Mineralys Therapeutics Executives Sell Shares - TradingView
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 - Investing.com
Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance
SEC Form DEF 14A filed by Mineralys Therapeutics Inc. - Quantisnow
SEC Form DEFA14A filed by Mineralys Therapeutics Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 - Investing.com Australia
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 By Investing.com - Investing.com Canada
Buy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market Potential - TipRanks
When (MLYS) Moves Investors should Listen - news.stocktradersdaily.com
Stifel maintains Buy on Mineralys stock with $45 target - Investing.com Australia
ACC25: Mineralys' uncontrolled hypertension drug aces trial - Pharmaphorum
Stifel maintains Buy on Mineralys stock with $45 target By Investing.com - Investing.com South Africa
Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks
Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial - TipRanks
Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics - TipRanks
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - The Manila Times
Mineralys Therapeutics Announces Late-Breaking Data from - GlobeNewswire
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) - TradingView
Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan
Mineralys Therapeutics, Inc. Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - Marketscreener.com
Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress - MSN
3 Brilliant Space Stocks to Buy Now and Hold for the Long Term - The Globe and Mail
Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.
Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
Mineralys Therapeutics to Host KOL Call to Discuss Clinical - GlobeNewswire
Mineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke Laffin - Nasdaq
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - The Manila Times
Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results - Stock Titan
MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Mineralys Therape - GuruFocus
Lorundrostat Shows Promise in Treatment of Uncontrolled and Resistant Hypertension in trials - Medical Dialogues
Buy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety Profile - TipRanks
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MSN
Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - The Manila Times
Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Insider Monkey
Mineralys Therapeutics Announces Closing of Underwriters’ - GlobeNewswire
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - Marketscreener.com
Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - StockTitan
10 Pump and Dump Stocks Favored by Hedge Funds - Insider Monkey
Mineralys to present hypertension drug trial results at ACC.25 By Investing.com - Investing.com Australia
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):